Fig. 3: Death or new neurological events during the first 12 months after randomization for the intention-to-treat population. | Nature Medicine

Fig. 3: Death or new neurological events during the first 12 months after randomization for the intention-to-treat population.

From: Genotype-stratified adjunctive dexamethasone for tuberculous meningitis in HIV-negative adults: a randomized controlled phase 3 trial

Fig. 3: Death or new neurological events during the first 12 months after randomization for the intention-to-treat population.

Kaplan–Meier curves are shown for the primary endpoint. The solid lines represent the estimated probability of event-free survival in each stratum. The colored shading represents the 95% CIs. A forest plot is shown displaying the hazard ratio (HR) and CIs, with corresponding confidence levels at 96% for CC and CT combined and 98.3% for CC. The points represent the estimated HRs in the primary endpoint between two treatment arms. The black lines represent the 95% CIs. The red vertical line demonstrates the noninferiority threshold at HR of 0.75. The dashed vertical line demonstrates the superiority threshold at HR of 1. For analysis, a Cox proportional hazard model was used, with MRC grade and LTA4H genotype as strata. Analyses are performed for the following populations: for CC and CT genotype combined, 613 participants; for CT genotype, 322 participants; and for CC genotype, 291 participants.

Back to article page